Amlodipine and valsartan
Pro Research Analysisby 
Searched over 200M research papers
Amlodipine and Valsartan: A Comprehensive Overview
Introduction to Amlodipine and Valsartan
Amlodipine and valsartan are widely used antihypertensive agents. Amlodipine is a calcium channel blocker (CCB), while valsartan is an angiotensin II receptor blocker (ARB). Both medications are effective in managing hypertension, either as monotherapy or in combination.
Pharmacokinetics and Bioequivalence
A study comparing the pharmacokinetics of a single-pill combination (SPC) of valsartan and amlodipine with their generic formulations found that both formulations are bioequivalent. The study used average bioequivalence (ABE) and reference-scaled average bioequivalence (RSABE) methods to evaluate the main pharmacokinetic parameters under fasting and postprandial conditions. The results showed that both formulations met the bioequivalence criteria and had similar safety profiles in healthy Chinese subjects .
Efficacy in Blood Pressure Reduction
Combination Therapy vs. Monotherapy
Several studies have demonstrated that the combination of amlodipine and valsartan is more effective in reducing blood pressure than either drug alone. In two randomized, double-blind, factorial trials, the combination achieved significantly greater reductions in mean sitting diastolic and systolic blood pressure compared to monotherapy or placebo. Approximately 80-90% of patients receiving the combination therapy achieved a response, defined as a mean sitting diastolic BP <90 mmHg or a ≥10 mmHg reduction from baseline . Another study confirmed that the combination therapy was associated with significantly greater reductions in mean sitting diastolic and systolic blood pressure compared to monotherapy .
Special Populations
The antihypertensive efficacy of the amlodipine/valsartan combination has been consistent across various subgroups, including the elderly, Black patients, and those with stage 2 hypertension . Additionally, a study focusing on Chinese patients found that the combination of amlodipine/valsartan 5/160 mg was more effective in lowering blood pressure than valsartan 160 mg alone .
Cardiovascular Outcomes
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial compared the effects of valsartan and amlodipine on cardiac morbidity and mortality in hypertensive patients at high cardiovascular risk. The study found no significant difference in the primary composite endpoint of cardiac mortality and morbidity between the two treatment groups, although amlodipine was more effective in reducing blood pressure, especially in the early period .
Effects on Left Ventricular Mass and Inflammation
A study comparing the effects of valsartan and amlodipine on left ventricular mass and reactive oxygen species (ROS) formation by monocytes in hypertensive patients with left ventricular hypertrophy (LVH) found that valsartan significantly reduced left ventricular mass index (LVMI) and ROS formation more than amlodipine. Valsartan also reduced C-reactive protein (CRP) levels, indicating its anti-inflammatory effects .
Safety and Tolerability
Both amlodipine and valsartan are generally well-tolerated. However, the incidence of peripheral edema is significantly lower in patients receiving the combination therapy compared to those treated with amlodipine monotherapy 26. In elderly patients with isolated systolic hypertension, valsartan showed similar efficacy but better tolerability compared to amlodipine, with a lower incidence of adverse effects such as peripheral edema .
Pharmacokinetic Interactions
A study investigating the pharmacokinetic interactions between amlodipine, valsartan, and rosuvastatin found that coadministration did not significantly affect the pharmacokinetic exposure to amlodipine and rosuvastatin, although the exposure to valsartan was decreased. All treatments were well tolerated .
Conclusion
The combination of amlodipine and valsartan offers superior blood pressure control compared to monotherapy, with a favorable safety profile. It is effective across various patient subgroups and has additional benefits such as reducing left ventricular mass and inflammation. These findings support the use of amlodipine/valsartan combination therapy as a robust option for managing hypertension.
Sources and full results
Most relevant research papers on this topic